+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population

SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population

Journal of Psychiatric Research 61: 33-39

Venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) type, is used to treat patients with major depressive disorder (MDD). Much evidence suggests that genetic polymorphisms may modulate serotonergic and noradrenergic function, thereby affecting the treatment efficacy of venlafaxine. The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. An 8-week naturalistic treatment study with venlafaxine was carried out in 243 Han Chinese patients with MDD. The patients were screened for seven single-nucleotide polymorphisms of the SLC6A2 gene. Of the enrolled patients, 161 completed the 8-week treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was used to assess the improvement of depressive symptoms in each subject from baseline to the endpoint. For better presentation of time-course change of remission status, a Cox regression analysis for remission incidence during the 8-week treatment was conducted. Between remitters and non-remitters, significant differences in genotype frequencies were observed in five of the investigated SLC6A2 variants (rs28386840, rs1532701, rs40434, rs13333066, rs187714). GCG haplotype (rs40434 - rs13333066 - rs187714) in the SLC6A2 gene showed a association with non-remission. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714). Our results suggest that the variation of the SLC6A2 gene is associated with treatment remission after venlafaxine in patients with MDD.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058798445

Download citation: RISBibTeXText

PMID: 25512257

DOI: 10.1016/j.jpsychires.2014.11.017

Related references

TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression. Pharmacopsychiatry 48(3): 95-103, 2016

HTR1A and HTR2A variants may not predict venlafaxine treatment response in China Han population with major depressive disorder. Psychiatry Research 270: 1179-1180, 2018

Common variants in SLC6A2, SLC6A3, DRD2, and major depressive disorder: an association study in the Chinese Han population. Psychiatric Genetics 27(3): 103-104, 2017

Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. American Journal of Psychiatry 174(5): 468-475, 2017

Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Journal of Clinical Psychiatry 64(3): 321-330, 2003

CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population. Clinical Neuropharmacology 42(2): 32-36, 2019

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. Journal of Clinical Psychopharmacology 18(1): 19-25, 1998

SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome. Pharmacopsychiatry 48(2): 81, 2015

Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. Journal of Clinical Pharmacy and Therapeutics 32(4): 353-363, 2007

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depression and Anxiety 16(1): 4, 2002

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. International Clinical Psychopharmacology 15(1): 29-34, 2000

An eight-week, open-label, uncontrolled, multicenter, Phase IV study of remission rates in outpatients and inpatients with major depression treated with venlafaxine. Current Therapeutic Research 63(8): 475-485, 2002

Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Journal of Clinical Psychopharmacology 30(4): 357-364, 2010

Achieving remission from depression with venlafaxine and venlafaxine extended release: A literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica 106(415 Suppl.): 24-30, 2002

Combining venlafaxine and mirtazapine for the treatment of major depression with dysthymia--"double depression". Revista Brasileira de Psiquiatria 30(3): 299-300, 2008